Back to Search
Start Over
Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
- Source :
-
Leukemia & Lymphoma . Jul2015, Vol. 56 Issue 7, p2039-2046. 8p. - Publication Year :
- 2015
-
Abstract
- Addition of etoposide to the R-CHOP chemotherapy regimen with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOEP) has resulted in improved survival in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). It is not known whether biological factors can predict this effect. In this study, 245 patients representing all young patients with high-risk DLBCL treated with R-CHOP or R-CHOEP in 2004-2012 in Denmark were extracted from the Danish lymphoma database. Patients were stratified according to cell of origin (COO) into germinal-center B-cell-like (GCB) or non-GCB by Hans' algorithm. Only in patients with the GCB phenotype was treatment with R-CHOEP associated with improved progression-free survival (PFS) and overall survival (OS) compared with R-CHOP. Patients with GCB phenotype treated with R-CHOEP also had superior OS compared with patients with non-GCB phenotype treated with R-CHOEP. This was not seen in R-CHOP treated patients. This could suggest that R-CHOEP should be restricted to patients with GCB phenotype. [ABSTRACT FROM AUTHOR]
- Subjects :
- *CANCER chemotherapy
*LYMPHOMAS
*CANCER patients
*B cells
*ETOPOSIDE
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 56
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 108562416
- Full Text :
- https://doi.org/10.3109/10428194.2014.982645